Primary membranous nephropathy (MN) is an autoimmune disease mainly caused by
autoantibodies against the recently discovered podocyte antigens: the M-type …

Membranous nephropathy is a major cause of nephrotic syndrome of non-diabetic origin in
adults. It is the second or third leading cause of end-stage renal disease in patients with …

Background A cyclic corticosteroid-cyclophosphamide regimen is the first-line therapy for
membranous nephropathy. Compared with this regimen, rituximab therapy might have a …

Membranous nephropathy (MN) is a glomerular disease that can occur at all ages. In adults,
it is the most frequent cause of nephrotic syndrome. In~ 80% of patients, there is no …

The complement cascade, traditionally considered an effector arm of innate immunity
required for host defense against pathogens, is now recognized as a crucial pathogenic …

Autoantibodies to the M-type phospholipase A 2 receptor (PLA 2 R) are sensitive and
specific for idiopathic membranous nephropathy. The anti-B cell agent rituximab is a …

Kidney biopsy is the gold standard to diagnose membranous nephropathy (MN).
Approximately 70%-80% of patients with primary MN have anti-phospholipase A2 receptor …

Antibodies to the phospholipase A2 receptor 1 (PLA2R1) have been reported in 70% of
cases of idiopathic membranous nephropathy (IMN). The genetic susceptibility of IMN has …

The phospholipase A 2 receptor (PLA 2 R) is the major target antigen in idiopathic
membranous nephropathy. The technique for measuring antibodies against PLA 2 R and …

The M-type phospholipase A2 receptor (PLA 2 R) is the major target antigen in idiopathic
membranous nephropathy with detectable autoantibodies in the serum of up to 70% of …